Laekna (HKG:2105) commenced its investigational new drug-enabling study for its LAE123 drug, according to a Thursday filing with the Hong Kong Exchange.

LAE123 inhibits activin type II receptors or ActRIIA/IIB and helps prevent sarcopenia or muscle weakness.

The company has advanced the drug to pre-clinical candidate declaration, the filing said.

Price (HKD): $15.04, Change: $-0.22, Percent Change: -1.44%